Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: A case report and review of the literature

被引：15

作者：

Fujii Y. ^{[1
]}

Hirahara N. ^{[1
]}

Kaji S. ^{[1
]}

Taniura T. ^{[1
]}

Hyakudomi R. ^{[1
]}

Yamamoto T. ^{[1
]}

Tajima Y. ^{[1
]}

机构：

[1] Department of Digestive and General Surgery, Shimane University, Faculty of Medicine, 89-1, Enyacho, Izumo-shi, Shimane-prefecture

来源：

Journal of Medical Case Reports | / 12卷 / 1期

基金：

日本学术振兴会;

关键词：

Bevacizumab; Breast cancer; Gastrointestinal perforation;

D O I：

10.1186/s13256-018-1619-x

中图分类号：

学科分类号：

摘要：

Background: Gastrointestinal perforation is known as a serious adverse event, but, for breast cancer, there are very few reports of gastrointestinal perforation. This report highlights gastrointestinal perforation caused by bevacizumab for breast cancer, which is of special interest because gastrointestinal perforations caused by bevacizumab are very rare in breast cancer. Case presentation: We describe the case of 54-year-old Japanese woman. She was diagnosed as having inoperable breast cancer T2 N1 M1 (pleura, peritoneum), Stage IV, and received chemotherapy by paclitaxel. There was reduction in the primary tumor and disappearance of the pleural effusion; however, the ascites did not change. We performed diagnostic laparoscopy which revealed that her whole peritoneum was thickened, and her small intestine, colon, and her omentum were grouped and formed an omental cake. We submitted a part of her peritoneum to pathological examination and diagnosed the peritoneum dissemination of breast cancer. On the basis of these results, paclitaxel and bevacizumab combination chemotherapy was started, and a decrease in ascites was seen. However, a gastrointestinal perforation occurred on 26th day of second cycle of bevacizumab + paclitaxel, and we performed an emergency operation. In the operation, the omental cake was resolved, and we could search the full length of the gastrointestinal tract. Two small perforations of her small intestine were seen. We performed simple closures for perforations, and peritoneal lavage and drainage. She was in a state of septic shock, but it improved. It was thought that the small intestinal perforations were caused by the bevacizumab-additional chemotherapy which was very effective. Conclusions: We report a very rare and valuable case. This case suggests that the risk of gastrointestinal perforation must be considered in a case of bevacizumab administration, and it is necessary to determine carefully the patient administered bevacizumab, regardless of the type of cancer. © The Author(s). 2018

引用

共 15 条

[1]

Mychaluk J., Piprot C., Sevestre H., Merviel P., Gondry J., Fauvet R., Intestinal perforation: An unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer, Presse Med, 38, pp. 1370-1374, (2009)

[2]

Lecarpentier E., Ouaffi L., Mir O., Berveiller P., Maurel M., Pujade-Lauraine E., Bouillot J.L., Veyrie N., Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases, Investig New Drugs, 29, pp. 1500-1503, (2011)

[3]

Gray R., Bhattacharya S., Bowden C., Miller K., Comis R.L., Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer, J Clin Oncol, 28, pp. 3239-3247, (2009)

[4]

Robert N.J., Dieras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., Et al., RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of Human epidermal Growth Factor Receptor 2-negative, locally recurrent or metastatic breast cancer, J Clin Oncol, 29, pp. 1252-1269, (2011)

[5]

Brufsky A., Rivera R.R., Hurvitz S.A., Bondarenko I.N., Smirnov V., Valero V., Et al., Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER-2 negative, locally recurrent or metastatic breast cancer (MBC), J Clin Oncol, 28, (2010)

[6]

Jain R.K., Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy, Nat Med, 7, pp. 987-989, (2001)

[7]

Kamba T., McDonald D.M., Mechanism of adverse effects of anti-VEGF therapy for cancer, Br J Cancer, 67, pp. 1788-1795, (2007)

[8]

Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 23, pp. 2335-2342, (2004)

[9]

Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., Et al., Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, 12, pp. 1539-1544, (2007)

[10]

Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Et al., Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, pp. 60-65, (2003)

← 1 2 →